Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

REFERENCES

• Amado , R. G. , Wolf , M. , Peeters , M. , Van Cutsem , E. , Siena , S. , Freeman , D. J. , Juan , T. , Sikorski , R. , Suggs , S. , Radinsky , R. , Patterson , S. D. , Chang , D. D. ( 2008 ). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer . J. Clin. Oncol. 26 ( 10 ): 1626 – 1634 .
   PubMed Web of Science ®Google Scholar
• Booth , C. M. , Calvert , A. H. , Giaccone , G. , Lobbezoo , M. W. , Eisenhauer , E. A. , Seymour , L. K. ( 2008a ). On behalf of the task force on methodology for the development of innovative cancer therapies. Design and conduct of Phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) . European J. Cancer 44 : 25 – 29 .
   PubMed Web of Science ®Google Scholar
• Booth , C. M. , Calvert , A. H. , Giaccone , G. , Lobbezoo , M. W. , Seymour , L. K. , Eisenhauer , E. A. ( 2008b ). On behalf of the task force on methodology for the development of innovative cancer therapies. Endpoints and other considerations in Phase I studies of targeted anticancer therapies: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) . European J. Cancer 44 : 19 – 24 .
   PubMed Web of Science ®Google Scholar
• Chen , C. , Beckman , R. A. ( 2009 ). Optimal dose-effective designs of Phase II proof of concept trials and associated go–no go decisions . JBS.
   Google Scholar
• Cheung , Y. K. ( 2009 ). Selecting promising treatments in randomized Phase II cancer trials with an active control . JBS.
   Google Scholar
• Holford , N. H. , Kimko , H. C. , Monteleone , J. P. , Peck , C. C. ( 2000 ). Simulation of clinical trials . Ann. Rev. Pharmacol. Toxicol. 40 : 209 – 234 .
   PubMed Web of Science ®Google Scholar
• Jung , S.-H. , George , S. L. ( 2009 ). Between-arm comparisons in randomized Phase II trials . JBS.
   Google Scholar
• Kocherginsky , M. , Cohen , E. E. W. , Karrison , T. ( 2009 ). Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents . JBS.
   Google Scholar
• Liu , P. Y. , LeBlanc , M. , Desai , M. ( 1999 ). False positive rates in randomized Phase II designs . Contr. Clin. Trials 20 : 343 – 352 .
   PubMedGoogle Scholar
• Onar , A. , Kocak , M. , Boyett , J. M. ( 2009 ). Continual reassessment method vs. traditional empirically based design: Modifications motivated by Phase I trials in pediatric oncology by the pediatric brain tumor consortium . JBS.
   Google Scholar
• O'Quigley , J. , Zohar , S. ( 2006 ). Experimental designs for Phase I and Phase I/II dose-finding studies . Br. J. Cancer 94 : 609 – 613 .
   PubMed Web of Science ®Google Scholar
• Ratain , M. J. , Karrison , T. G. ( 2007 ). Testing the wrong hypothesis in Phase II oncology trials: There is a better alternative . Clin. Cancer Res. 13 ( 3 ): 781 – 782 .
   PubMed Web of Science ®Google Scholar
• Ratain , M. J. , Sargent , D. J. ( 2009 ). Optimising the design of Phase II oncology trials: The importance of randomization . European J. Cancer. 45 : 275 – 280 .
   PubMed Web of Science ®Google Scholar
• Redman , M. , Crowley , J. ( 2007 ). Small randomized trials . J. Thorac. Oncol. 2 ( 1 ): 1 – 2 .
   Google Scholar
• Rogatko , A. , Schoeneck , D. , Jonas , W. , Tighiouart , M. , Khuri , F. R. , Porter , A. ( 2007 ). Translation of innovative designs into Phase I trials . J. Clin. Oncol. 25 ( 31 ): 4982 – 4986 .
   PubMed Web of Science ®Google Scholar
• Romond , E. H. , Perez , E. A. , Bryant , J. , Suman , V. J. , Geyer , C. E. Jr. , Davidson , N. E. , Tan-Chiu , E. , Martino , S. , Paik , S. , Kaufman , P. A. , Swain , S. M. , Pisansky , T. M. , Fehrenbacher , L. , Kutteh , L. A. , Vogel , V. G. , Visscher , D. W. , Yothers , G. , Jenkins , R. B. , Brown , A. M. , Dakhil , S. R. , Mamounas , E. P. , Lingle , W. L. , Klein , P. M. , Ingle , J. N. , Wolmark , N. ( 2005 ). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N. Engl. J. Med. 353 ( 16 ): 1673 – 1684 .
   PubMed Web of Science ®Google Scholar
• Rubenstein , L. V. , Korn , E. L. , Freidlin , B. , Hunsberger , S. , Ivy , S. P. , Smith , M. A. ( 2005 ). Design issues of randomized Phase II trials and a proposal for Phase II screening trials . J. Clin. Oncol. 23 ( 28 ): 7199 – 7206 .
   Google Scholar
• Sargent , D. J. , Goldberg , R. M. (2001). A flexible design for multiple armed screening trials. Stat. Med. 20(7):1051–1060.
   PubMed Web of Science ®Google Scholar
• Simon , R. , Wittes , R. E. , Ellenberg , S. S. ( 1985 ). Randomized Phase II clinical trials . Cancer Treat Rep. 69 ( 12 ): 1375 – 1381 .
   PubMedGoogle Scholar
• Simon , R. , Thall , P. F. , Ellenberg , S. S. ( 1994 ). New designs for the selection of treatments to be tested in randomized clinical trials . Stat. Med. 13 ( 5–7 ): 417 – 429 .
   Google Scholar
• Sun , L. Z. , Chen , C. , Patel , K. ( 2009 ). Optimal two-stage randomized multinomial designs for Phase II oncology trials . JBS.
   Google Scholar
• Taylor , J. M. G. , Braun , T. , Li , Z. ( 2006 ). Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design . Clinical Trials ( 4 ): 335 – 348 .
   Google Scholar
• Thall , P. F. , Simon , R. ( 1994 ). Practical Bayesian guidelines for Phase IIB clinical trials . Biometrics 50 ( 2 ): 337 – 349 .
   PubMed Web of Science ®Google Scholar
• Thall , P. F. , Estey , E. H. ( 2005 ). Some ethical issues in Phase II trials in acute leukemia . Clinical Advances Hem. & Onc. 3 ( 12 ): 943 – 948 .
   Google Scholar
• Vickers , A. J. , Ballen , V. , Scher , H. I. ( 2007 ). Setting the bar in Phase II trials: The use of historical data for determining “go/no go” decision for definitive Phase III testing . Clin. Cancer Res. 13 ( 3 ): 792 – 796 .
   Google Scholar
• Wieand , H. S. ( 2005 ). Randomized Phase II trials: What does randomization gain? J. Clin. Oncol. 23 ( 9 ): 1794 – 1795 .
   PubMed Web of Science ®Google Scholar
• Zohar , S. , Chevret , S. ( 2007 ). Recent developments in adaptive designs for Phase I/II dose-finding studies . J. Biopharm. Stat. 17 ( 6 ): 1071 – 1083 .
   PubMed Web of Science ®Google Scholar